NSC
57
-7
PM
64
6
CTAS
56
-8
R
75
-2
JBHT
60
-3
PNR
71
-3
XYL
39
-2
CTSH
63
-2
CMCSA
53
-2
FCX
56
2
PYPL
56
-6
AES
44
3
HPE
48
-22
DOV
69
-4
ORLY
66
-3
HP
37
-8
QRVO
6
2
AIV
60
-4
RRC
58
-2
VTR
50
-5
NSC
57
-7
PM
64
6
CTAS
56
-8
R
75
-2
JBHT
60
-3
PNR
71
-3
XYL
39
-2
CTSH
63
-2
CMCSA
53
-2
FCX
56
2
PYPL
56
-6
AES
44
3
HPE
48
-22
DOV
69
-4
ORLY
66
-3
HP
37
-8
QRVO
6
2
AIV
60
-4
RRC
58
-2
VTR
50
-5
Financhill
Back

Cidara Therapeutics 10K Form

Buy
62

CDTX
Cidara Therapeutics

Last Price:
14.66
Seasonality Move:
7.85%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive CDTX News And Ratings

See the #1 stock for the next 7 days that we like better than CDTX

CDTX Financial Statistics

Sales & Book Value

Annual Sales: $63.91M
Cash Flow: $-36.8M
Price / Cash Flow: 0
Annual Sales: $16.41
Price / Book: 0.88

Profitability

EPS (TTM): -25.36000
Net Income (TTM): $-120.73M
Gross Margin: $62.38M
Return on Equity: 0%
Return on Assets: 0%

Cidara Therapeutics Earnings Forecast

Key Cidara Therapeutics Financial Ratios

  • The Gross Profit Margin over the past 5 years for CDTX is 97.62%.
  • The Selling, General & Administrative Expenses for CDTX have been equal to 28.69% of Gross Profit Margin.
  • The Research & Development expenses have been 107.24% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • Per Share Earnings over the last 11 years have been positive in 6 years.

Cidara Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: CDTX
CUSIP: 171757
Website: cidara.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

CDTX Technical Analysis vs Fundamental Analysis

Buy
62
Cidara Therapeutics (CDTX) is a Buy

Is Cidara Therapeutics a Buy or a Sell?